AmengualOAtsumiT. Antiphospholipid syndrome, “the best prophet of the future”. Modern Rheumatology/the Japan Rheumatism Association2018; 28: 409–416.
2.
OkuKAtsumiTBohgakiMet al.Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis2009; 68: 1030–1035.
3.
JiangYAraseNKohyamaMet al.Transport of misfolded endoplasmic reticulum proteins to the cell surface by MHC class II molecules. Int Immunol2013; 25: 235–246.
4.
AraseH. Rheumatoid rescue of misfolded cellular proteins by MHC class II molecules: a new hypothesis for autoimmune diseases. Adv Immunol2016; 129: 1–23.
5.
JinHAraseNHirayasuKet al.Autoantibodies to IgG/HLA class II complexes are associated with rheumatoid arthritis susceptibility. Proc Natl Acad Sci USA2014; 111: 3787–3792.
6.
TanimuraKJinHSuenagaTet al.Beta2-glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome. Blood2015; 125: 2835–2844.
7.
CarontiBCalderaroCAlessandriCet al.Beta2-glycoprotein I (beta2-GPI) mRNA is expressed by several cell types involved in anti-phospholipid syndrome-related tissue damage. Clin Exp Immunol1999; 115: 214–219.
8.
ChamleyLWAllenJLJohnsonPM. Synthesis of beta2 glycoprotein 1 by the human placenta. Placenta1997; 18: 403–410.
9.
AraseNTanimuraKJinHet al.Novel autoantibody against the beta2-glycoprotein I/human leucocyte antigen-DR complex in patients with refractory cutaneous ulcers. Br J Dermatol2018; 178: 272–275.
10.
BenagianoMGerosaMRomagnoliJet al.β2 Glycoprotein I recognition drives Th1 inflammation in atherosclerotic plaques of patients with primary antiphospholipid syndrome. J Immunol2017; 198: 2640–2648.
11.
ErkanDVegaJRamonGKozoraELockshinMD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum2013; 65: 464–471.
